SAN Share Price

Open 82.17 Change Price %
High 83.72 1 Day 0.60 0.72
Low 82.14 1 Week 0.47 0.57
Close 83.47 1 Month 2.75 3.41
Volume 1944737 1 Year 14.45 20.94
52 Week High 83.73
52 Week Low 62.50
SAN Important Levels
Resistance 2 84.93
Resistance 1 84.33
Pivot 83.11
Support 1 82.61
Support 2 82.01
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
AVT 0.09 -10.00%
AVT 0.09 -10.00%
AVT 0.09 -10.00%
AVT 0.09 -10.00%
OXI 0.09 -10.00%
OXI 0.09 -10.00%
STAL 375.02 -8.53%
FED 13.00 -8.52%
FED 13.00 -8.52%
FIPP 0.13 -7.14%
More..

Sanofi (EPA: SAN)

SAN Technical Analysis 5
As on 27th Mar 2017 SAN Share Price closed @ 83.47 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 74.00 & Strong Buy for SHORT-TERM with Stoploss of 79.32 we also expect STOCK to react on Following IMPORTANT LEVELS.
SAN Target for March
1st Target up-side 85.54
2nd Target up-side 88.57
3rd Target up-side 91.6
1st Target down-side 76.88
2nd Target down-side 73.85
3rd Target down-side 70.82
SAN Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.sanofi-aventis.com
SAN Address
SAN
54, Rue La Bo
Paris, 75008
France
Phone: 33 1 53 77 40 00
SAN Latest News
Sanofi SA (SAN) Given a €96.00 Price Target at Deutsche Bank AG   Sports Perspectives   - 27th Mar 17
Sanofi SA (ADR) (SNY) Reaches $45.41 52-Week High, Neptune Technologies ...   Herald KS   - 27th Mar 17
Sanofi SA (SAN) PT Set at €96.00 by Deutsche Bank AG   Chaffey Breeze   - 24th Mar 17
Sanofi SA (ADR) (NYSE:SNY) Said to Be in Talks to Acquire Flexion Therapeutics ...   Library For Smart Investors   - 24th Mar 17
Sanofi's Prescription for Growth: Drug Sales in the Middle Kingdom   Wall Street Journal (subscription)   - 21st Mar 17
Sanofi SA: Filing of the 2016 US Form 20-F and French “Document de Référence ...   The Wall Street Transcript   - 03rd Mar 17
Sanofi Sells 5 Over-the-Counter Drugs for $88M (SNY)   Investopedia   - 13th Feb 17
Flat Prospects for Sanofi in the Near Future? (SNY)   Investopedia   - 23rd Jan 17
M&A Drama Inspires Rare Round of Sanofi SA (SNY) Call Trading   Schaeffers Research (blog)   - 22nd Dec 16
Think Sanofi SA (ADR) (SNY) Stock When You Think Big Pharma   Investorplace.com   - 09th Dec 16
Interactive Technical Analysis Chart Sanofi ( SAN EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sanofi
SAN Business Profile
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.